Who Owns TG Therapeutics Stock?
NASDAQ: TGTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 78.61%
- Held by insiders
- 7.88%
- Institutional holders
- 583
- Institutions 78.6%
- Insiders 7.9%
- Public and other 13.5%
Who owns TG Therapeutics stock?
Institutional investors own about 78.6% of TG Therapeutics's shares, spread across 583 institutions that file 13F reports. That level of institutional ownership is high, typical of large, widely followed companies. Insiders, including executives, directors and large founding shareholders, hold 7.88% of TGTX.
The largest institutional holders are Blackrock Inc. (14.98%), State Street Corporation (5.62%) and Vanguard Portfolio Management LLC (5.21%). Together, the top 10 institutions control 41.8% of shares outstanding. In their latest filings, 8 of the top 10 institutions increased their TGTX positions and 2 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of TGTX
| Institution | Shares | % Held | Change |
|---|---|---|---|
| Blackrock Inc. | 22.63M | 14.98% | +2.6% |
| State Street Corporation | 8.49M | 5.62% | +9.0% |
| Vanguard Portfolio Management LLC | 7.88M | 5.21% | -1.0% |
| Vanguard Capital Management LLC | 6.26M | 4.14% | +1.7% |
| Geode Capital Management, LLC | 3.70M | 2.45% | +1.7% |
| Shaw D.E. & Co., Inc. | 3.40M | 2.25% | +476.4% |
| Soleus Capital Management, L.P. | 2.93M | 1.94% | -27.3% |
| Price (T.Rowe) Associates Inc | 2.77M | 1.83% | +337.4% |
| Congress Asset Management Co | 2.61M | 1.72% | +0.3% |
| Two Sigma Investments, LP | 2.47M | 1.63% | +60.1% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of TGTX
| Fund | Shares | % Held |
|---|---|---|
| iShares Trust-iShares Core S&P Small-Cap ETF | 8.45M | 5.59% |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 4.38M | 2.90% |
| iShares Trust-iShares Russell 2000 ETF | 3.77M | 2.49% |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 3.16M | 2.09% |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.70M | 1.79% |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 1.82M | 1.20% |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 1.59M | 1.05% |
| First TRT Exch-Trd Fd.-First TRT NYSE Arca Biotechnology Index Fd. | 1.59M | 1.05% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.51M | 1.00% |
| iShares Trust-iShares Russell 2000 Growth ETF | 1.36M | 0.90% |
Frequently asked questions
Who is the largest shareholder of TG Therapeutics?
Blackrock Inc. is the largest institutional shareholder of TGTX, owning 14.98% of shares outstanding (22.63M shares) as of its latest 13F filing.
What percentage of TG Therapeutics is owned by institutions?
Institutions own about 78.6% of TGTX shares and 85.3% of the public float.
How much of TG Therapeutics do insiders own?
Insiders, such as officers and directors, own about 7.88% of TGTX shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.